-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
202132,(PhIRDA)(RDPAC),《——:2015-2020》(“”)。《》,、、(、)、,,,、,。,“”(),《》。
2020 is the final year of the major scientific and technological projects of "Major New Drug Development"; 2021 is the beginning year of the continued implementation of the innovation-driven development strategy during the "14th Five-Year Plan".
"2015-2020 Development Review and Future Prospects" is the first in a series of research reports on "Building China's Pharmaceutical Innovation Ecosystem", focusing on reviewing the construction of China's pharmaceutical innovation ecosystem in the past five years, focusing on the policy environment, capital investment, and innovation The progress of the main body's capacity building will summarize the output of China's pharmaceutical innovation from the two aspects of "quantity" and "quality", and give a preliminary outlook on the construction of China's pharmaceutical innovation ecosystem in the next five years.
1.
1.
1.
1.
2.
2.
3.
3.
4.
4.
At the same time, the report believes that the quality of China's pharmaceutical innovation needs to be improved, and there are phenomena such as agglomeration of targets and homogeneous innovation in research and development.
2.
2.
Facing the complicated domestic and international environmental changes, the new crown epidemic has pushed China's innovative medicine to the international stage.
In this context, the development of China's pharmaceutical innovation ecosystem in the next five years should focus on three key points: First, enhance the competitiveness of the pharmaceutical innovation industry with "new drugs on the market" as the core.
Achieve higher-quality development through deeper reforms and higher levels of openness.
From the "following" of the third echelon in the past, to the "parallel running" of the second echelon in the past, it will move towards the "leading" of the first echelon in the future.
The second is to improve the accessibility of innovative drugs with "patient benefit" as the core.
Increase investment in health and health, and strengthen the efficiency of capital use to use innovative drugs with high clinical value, help people to live a healthy life, strengthen early diagnosis and prevention of diseases to achieve a higher return on capital investment, and reduce cancer, chronic diseases, and infectious diseases The third is to ensure the sustainability of the industry with "returns on innovation" as the core.
Ensure the continuous R&D investment of capital and pharmaceutical companies, and benefit patients with more breakthrough innovations.
In the past five years, China has established a vital pharmaceutical innovation industry based on the advanced concepts of the innovation ecosystem, top-level design vigorously promoted from top to bottom, fair competition and highly integrated innovative enterprises.
An important historical node for a large manufacturing country to become a strong pharmaceutical innovation country.
Looking forward to the next five years, we still need to look far ahead, take advantage of the situation, achieve higher-quality development through deeper reforms, higher levels of openness, and international cooperation, and promote and realize the construction of a "human health and health community" as a strong country in pharmaceutical innovation.
Ambitious goals.
[Editorial Postscript] China's pharmaceutical industry is facing a great opportunity to leapfrog high-quality development.
The development direction and plan for the next five years are crucial to building China's pharmaceutical innovation power.
What are the weak links in the construction of China's pharmaceutical innovation ecological environment at this stage? What will be the future development direction? How to improve China's current weak links? How to integrate the efficiency and quality of research and development with international standards? Innovation-oriented diversified payments For how to construct the guarantee system, please pay attention to the content of the follow-up series of reports on China's pharmaceutical innovation ecology.
China Pharmaceutical Innovation Promotion Association
China Pharmaceutical Innovation Promotion Association The China Association for the Promotion of Pharmaceutical Innovation (hereinafter referred to as the China Association for the Promotion of Pharmaceuticals) was established in 1988 and is a non-profit national 4A social organization registered with the Ministry of Civil Affairs.
Adhering to the tenet of “innovation, industrialization, and internationalization”, the China Association for the Promotion of Pharmaceuticals has long been committed to the close integration of “production, education, research and funding” to promote the innovation and development of the pharmaceutical industry.
It has become an enterprise integrating pharmaceutical innovation and R&D.
The pharmaceutical innovation industrialization promotion platform composed of scientific research institutions, clinical research institutions, innovation service institutions and pharmaceutical investment institutions currently has 151 member units.
The association has established drug research and development, drug clinical trial research, pharmaceutical policy, pharmaceutical innovation investment, innovative research and development services, cardiovascular drug clinical research, international innovative drug supervision, clinical research on anti-tumor drugs, clinical research on cranial nerve drugs, and compliance with pharmaceutical companies Professional committees have formed a full-chain organizational structure covering drug R&D, production, use, investment and financing with innovation as the core and promoting innovation as the goal, and continue to expand international exchanges as a member of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) channel.
RDPAC
RDPAC The Pharmaceutical Research and Development Industry Committee of the China Association of Enterprises with Foreign Investment (RDPAC) is a non-profit organization composed of 44 multinational pharmaceutical companies with research and development capabilities, and is affiliated to the "China Association of Enterprises with Foreign Investment.
" As of June 2020, RDPAC member companies have established 47 factories and 25 R&D centers in Mainland China.
From July 2015 to June 2020, RDPAC member companies have introduced more than 206 innovative drugs to the Chinese market.
RDPAC members share the same aspiration with the Chinese government and local pharmaceutical companies, that is, hope that China will become a major country in pharmaceutical innovation.
RDPAC looks forward to having the opportunity to work together and develop collaboratively with the Chinese government to realize this wish and enable innovative drugs to benefit more Chinese and global patients.
Click to read the original text to get the full report
Click to read the original text to get the full report